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0090-4295African American (AA) men undergoing repeat biopsy, and to compare accuracy for predicting
repeat biopsy outcome to prior studies conducted in predominantly Caucasian populations.MATERIALS AND
METHODSThe study population consisted of 211 AA men from 7 urology centers across the United States;
all of whom were undergoing 12-core transrectal ultrasound-guided repeat biopsy within
30 months from a negative index biopsy. All biopsy cores from the negative index biopsy were
proﬁled for the epigenetic biomarkers GSTP1, APC, and RASSF1 using ConﬁrmMDx for Prostate
Cancer (MDxHealth, Irvine, CA).RESULTS Upon repeat biopsy, 130 of 211 subjects (62%) had no prostate cancer (PCa) detected and 81 of
211 (38%) were diagnosed with PCa. Of the subjects with PCa, 54 (67%) were diagnosed with
Gleason score (GS) ≤6 PCa and 27 (33%) with GS ≥7 disease. For detection of PCa at repeat
biopsy, ConﬁrmMDx sensitivity was 74.1% and speciﬁcity was 60.0%, equivalent to prior studies
(P= .235 and .697, respectively). For detection of GS ≥7 PCa, sensitivity was 78% and speciﬁcity
was 53%. The negative predictive values for detection of all PCa and GS ≥7 PCa were 78.8%
and 94.2%, respectively.CONCLUSION In this group of AA men, we successfully validated an epigenetic assay to assess the need for repeat
biopsy. Results were consistent with previous studies from predominantly Caucasian populations.
Therefore, the ConﬁrmMDx assay is a useful tool for risk stratiﬁcation of AA men who had an ini-
tial negative biopsy. UROLOGY 128: 62−65, 2019. © 2018 The Author(s). Published by
Elsevier Inc.Men with 1 or more negative prostate biopsiespresent a dilemma for clinicians and patientsthemselves. Because of limitations of the cur-
rent standard of care, 60%-70% of initial prostate biopsies
fail to detect cancer, and 20%-30% of men receive false
negative biopsy results.1,2 The fear that cancer was missedally to the work.
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Thleads to repeat biopsies, which increases health-care costs
and exposes men to potential morbidity, including post-
biopsy infection and sepsis.3-5 There is an unmet need for
more accurate diagnostic tools to improve risk stratiﬁca-
tion and to help identify men who are most likely to bene-
ﬁt from a repeat biopsy.
Cancer-speciﬁc DNA methylation occurs early in the
oncogenic process, and these epigenetic changes can be
detected in prostate biopsy tissue at a distance from the
actual tumor through a cancer-associated ﬁeld effect.6
ConﬁrmMDx for Prostate Cancer (MDxHealth, Irvine,
CA) is a multiplex epigenetic assay that measures DNA
methylation of GSTP1, APC, and RASSF1. The assay
detects the presence of cancer in adjacent histologically
negative prostate tissue.6 When performed on tissue from
cancer-negative prostate biopsies, ConﬁrmMDx can
improve accuracy for predicting repeat biopsy outcome
relative to the current standard-of-care risk factors.7 In a
large, blinded clinical validation study, the assay yielded a
negative predictive value (NPV) of 90% for detection of© 2018 The Author(s). Published by Elsevier Inc.
is is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)
cancer at biopsy, but only 42 of 350 study subjects were
African American (AA).8
Prostate cancer (PCa) incidence and mortality rates are
signiﬁcantly higher in AA men compared to Caucasian
American men.9 AAs have a 1.7-fold increased incidence
and a 2.3-fold higher PCa mortality rate compared to US
non-Hispanic Caucasians (North American Association
of Central Cancer Registries [NAACCR] 2016 and
National Center for Health Statistics [NCHS] 2016).
Although other factors may contribute to these differen-
ces, it is increasingly evident that this disparity has a
molecular basis.10 In fact, differences in genetic alterations
have been reported in malignant prostate tissues from
patients of diverse racial backgrounds.10,11 These ﬁndings
have potential implications for molecular tests used for
cancer detection and management as the same racial
diversity could apply to biomarkers.
All published ConﬁrmMDx studies to date have been
performed in predominantly Caucasian subjects. In this
study, we evaluated the performance of ConﬁrmMDx for
Prostate Cancer in a cohort of AA men undergoing repeat
prostate biopsy.MATERIALS AND METHODS
The study population consisted of 211 AA men from 7 urology
centers across the United States, all of whom were undergoing
standard 12-core transrectal ultrasound-guided repeat biopsy
within 30 months from a cancer-negative index biopsy. The sites
identiﬁed eligible subjects in a retrospective, consecutive man-
ner starting from patients biopsied at the clinics at study initia-
tion in 2011. All subjects had been screened for PCa and had
received their index biopsy based on known risk factors (eg, ele-
vated serum prostate-speciﬁc antigen level, abnormal digital rec-
tal examination, and clinical symptoms). Men with atypical
small acinar proliferation at index biopsy were excluded. Histo-
pathology review was performed on all available tissue samplesTable 1. Subject demographics
Parameter
Cance
Age (y) Mean
Median
Range (4
Serum PSA (ng/mL) Mean
Median
Range (0.6
DRE result (N, %) Normal 45
Suspicious 15
N/A 21
Gleason sum(N, %) 6 54
7 (3+4) 15
7 (4+3) 6
8 4
9 2
Clinical stage (N, %) T1c 56
T2a 7
T2c 3
N/A 15
DRE, digital rectal examination; N/A, not applicable; PSA, prostate-spec
UROLOGY 128, 2019to verify the absence of adenocarcinoma or atypical small acinar
proliferation. We requested 40m of each archived, formalin-
ﬁxed, parafﬁn-embedded tissue core block from the initial
biopsy. However, in the event of limited excess tissue, a mini-
mum of 20m from formalin-ﬁxed, parafﬁn-embedded tissue cores
were used. After completion of all analyses with the epigenetic
assay, clinical and patient characteristics were veriﬁed and
updated with data from subsequent biopsies as necessary.
All cancer-negative biopsy cores were tested in a random,
blinded fashion using ConﬁrmMDx for Prostate Cancer, a multi-
plexed quantitative DNA methylation-speciﬁc polymerase chain
reaction assay for the epigenetic biomarkers GSTP1, APC, and
RASSF1.6,12 The methylation ratio of all 3 genes was determined
relative to that of the ACTB reference gene. Predetermined ana-
lytical cutoff values for determining methylation status of each
gene were identical to those used in the independent MATLOC
(Methylation Analysis to Locate Occult Cancers) and DOCU-
MENT (Detection of Cancer Using Methylation Events in Neg-
ative Tissue) studies.7,8 Assay results were considered positive if
any core yielded methylation signal above the pre-established
threshold.
The clinical performance for detection of any cancer, or Glea-
son score (GS) ≥7 cancer, was assessed and compared to results
from previous studies. The chi-square test was used to compare
proportions, including sensitivity and speciﬁcity values across
different studies, and Mann-Whitney test was used for compar-
ing continuous variables.RESULTS
Clinical characteristics of the subject population are shown in
Table 1. Upon repeat biopsy, 130 subjects (62%) had no PCa
detected and 81 (38%) were diagnosed with PCa. Of the 81 sub-
jects with PCa, 54 (67%) were diagnosed with GS ≤6 PCa and
27 (33%) with GS ≥7 disease. There was no difference in age,
serum prostate-speciﬁc antigen level, or digital rectal examina-
tion result between PCa-positive and PCa-negative groups.
Table 2 shows ConﬁrmMDx clinical performance characteris-
tics for detection of any cancer or high-grade PCa at repeatr (N =81) Benign (N=130) P Value
64 65 .366
63 65
6-86) (43-83)
8.4 8.0 .298
6.2 6.6
-61.6) (0.8-30.8)
(55%) 81 (62%) .331
(19%) 9 (7%)
(26%) 40 (31%)
(66%)
(19%)
(7%)
(5%)
(3%)
(69%)
(9%)
(4%)
(18%)
ific antigen.
63
Table 2. Clinical performance characteristics
Detection of Any Cancer at Biopsy
Parameter Value 95% CI
Sensitivity 74.1% 63.1%-83.1%
Specificity 60.0% 51.1%-68.5%
Disease prevalence 38.4% N/A
PPV 53.6% 47.4%-59.6%
NPV 78.8% 71.5%-84.6%
Detection of High-grade Cancer at Biopsy
Sensitivity 77.8% 57.7%-91.4%
Specificity 52.7% 45.2%-60.1%
Disease prevalence 12.8% N/A
PPV 19.4% 15.8%-23.7%
NPV 94.2% 88.7%-97.1%
CI, confidence interval; NPV, negative predictive value; PPV, posi-
tive predictive value.biopsy. The 2£ 2 contingency tables used to generate these
results may be found in Supplementary Table S1. For detection
of PCa at biopsy, sensitivity was 74.1% and speciﬁcity was
60.0%. For high-grade cancer detection (GS6 or benign pathol-
ogy considered “negative”), sensitivity was 77.8% and speciﬁcity
was 52.7%. The NPVs for PCa and high-grade PCa were 78.8%
and 94.2%, respectively.
We then compared ConﬁrmMDx clinical performance from
this cohort to 2 published multicenter studies7,8 conducted in
primarily Caucasian populations (Table 3). For detection of can-
cer at repeat biopsy, there were no signiﬁcant differences in sen-
sitivity (P= .235) or speciﬁcity (P= .697). We also evaluated
ConﬁrmMDx clinical performance by age range (Table 4). Sub-
jects were divided into 3 groups: <55 years, 55-69 years, and
≥70 years old. No signiﬁcant differences in sensitivity (P= .418)
or speciﬁcity (P= .213) were observed between age groups,
although the study was not speciﬁcally powered for this analysis.DISCUSSION
The results from this study provide external validation for
the use of ConﬁrmMDx to help guide repeat biopsy deci-
sion-making for AA men. Furthermore, ConﬁrmMDxTable 3. Comparison of clinical performance characteristics vs
Parameter MATLOC
Number of subjects 483
Sensitivity (95% CI) 68% (57%-77%)
Specificity (95% CI) 64% (59%-69%)
DOCUMENT, Detection of Cancer Using Methylation Events in Negative
Table 4. ConfirmMDx clinical performance by age range
Parameter <55 y
Total number of subjects 28
Cancer-positive (%) 11 (39%)
Sensitivity (95% CI) 64% (35%-85%)
Specificity (95% CI) 77% (52%-91%)
64clinical sensitivity and speciﬁcity were equivalent to pre-
viously published studies conducted in primarily Cauca-
sian men. This ﬁnding is especially important when
considering that several PCa oncologic molecular path-
ways demonstrate substantial racial differences. Powell
and Bollig-Fischer reported on multiple molecular PCa
differences in AAs compared to Caucasian Americans
including tumor suppressor genes, ERG, and single-nucle-
otide polymorphisms, in addition to various gene ampliﬁ-
cations and deletions related to oncogenesis like androgen
receptor signaling.13 Some of these molecular differences
may also affect molecular tests that aid in diagnosis of
PCa.
Therefore, it is of special importance to investigate the
scientiﬁc validity of speciﬁc molecular tools in AA men.
It is also of note that molecular testing with this epige-
netic assay has veriﬁable objective results that are repro-
ducible and not subject to variability based on location,
interpretation, or operator. Additionally, when molecular
testing is used after validation in AA cohorts, it has the
potential to positively impact health-care disparity related
to PCa outcomes. Positively impacting health-care dispar-
ities in diseases related to speciﬁc populations is an impor-
tant objective of the US Department of Health and
Human Services.14
Similarly, in the recent 2017 US Preventative Services
Task Force “Draft Proposal,” research related to PCa diag-
nosis and treatment is speciﬁcally recommended: “The
USPSTF strongly encourages research on screening for and
treatment of prostate cancer in African American men. It is
important to consider both the potential additional beneﬁts and
harms to fully understand the value of screening. Studies are
needed to conﬁrm that African American men who undergo
screening receive similar or greater reductions in prostate can-
cer mortality compared with men in the general population, as
well as to explore the optimal screening frequency and whether
beginning screening before age 55 years provides additional
beneﬁts in African American men. Studies are also needed to
better understand strategies to mitigate harms and maximize
beneﬁts of screening, diagnostic follow up, and treatmentprevious studies
DOCUMENT This Study
320 211
62% (52%-72%) 74% (63%-83%)
64% (57%-70%) 60% (51%-69%)
Tissue; MATLOC, Methylation Analysis to Locate Occult Cancers.
55-69 y ≥70 y
113 69
47 (42%) 23 (43%)
70% (56%-81%) 83% (62%-94%)
61% (49%-72%) 52% (38%-66%)
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(including active surveillance) in African American men. It is
also important that research and quality improvement activities
continue to work to eliminate disparities in access to high-qual-
ity care for men with prostate cancer”.
The objectives and ﬁndings of this study align with the
US Preventative Services Task Force's recommendations
for more research targeted in AA men at increased risk for
PCa. In the context of increased concern about the risk of
PCa in AA men, the decision to perform a repeat prostate
biopsy after a negative initial biopsy needs to be consid-
ered carefully. The risk of missing a signiﬁcant cancer in a
population that has increased PCa mortality is a troubling
concern. Therefore, to avoid the second biopsy, a tool
that provides a high NPV has the potential for actionable
utility. This epigenetic assay performed in that desired
fashion by providing an NPV over 90%, and more speciﬁ-
cally over 96% for high risk PCa. Although this study was
multi-institutional and of broad geographic diversity, we
encourage additional research studies that may contribute
to this collective body of research in the AA population
at risk for PCa.
One important limitation of this study is noted. All
enrolled subjects received a repeat prostate biopsy. The
results therefore apply to a group of men who, despite neg-
ative initial biopsy results, had clinical characteristics sus-
picious enough to recommend repeat biopsy. The true
prevalence of PCa in patients who had an initial biopsy,
but did not have a repeat biopsy, is unknown. Therefore,
the results may not be generalizable to the population of
AA men at large with a negative initial biopsy who do
not have sufﬁcient clinical suspicion to consider a repeat
biopsy.CONCLUSION
The ConﬁrmMDx epigenetic assay improved the identiﬁ-
cation of AA men at risk for occult high-grade PCa upon
repeat biopsy. Risk stratiﬁcation was demonstrated for
both the presence of PCa and high-grade PCa, with clini-
cal sensitivity and speciﬁcity equivalent to previous stud-
ies performed on cohorts that were predominantly
Caucasian. The assay's high NPV provides useful informa-
tion to help identify men who could potentially avoid or
delay an invasive repeat prostate biopsy procedure with its
associated risks. Although the ConﬁrmMDx positive pre-
dictive value was lower than the NPV in this study, the
assay did increase the rate of cancer detection and mayUROLOGY 128, 2019help urologists better select men who would likely beneﬁt
from repeat biopsy to determine the presence of PCa.
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